AbbVie — Valuation, Funding & Investors

We're still building this profile — here is what Pulse has covered.

Recent changes

Sep 21, 2026Sep 21, 2026ADARx Sets Terms For $350M IPO, AbbVie Buys In Pulse story

Latest Pulse

Sep 21, 2026ADARx Sets Terms For $350M IPO, AbbVie Buys InADARx Pharmaceuticals set terms for a $350 million Nasdaq IPO at $15-$17 a share targeting a $1.74 billion valuation, with AbbVie agreeing to buy a roughly 4.9% stake in a concurrent private placement.→

Coverage Timeline

newest first

Sep 21, 2026IPOADARx Sets Terms For $350M IPO, AbbVie Buys In$350M IPO→

All Coverage

IPO· Sep 21, 2026

ADARx Sets Terms For $350M IPO, AbbVie Buys In

IPO$350M IPO

ADARx Sets Terms For $350M IPO, AbbVie Buys In

ADARx Pharmaceuticals set terms for a $350 million Nasdaq IPO at $15-$17 a share targeting a $1.74 billion valuation, with AbbVie agreeing to buy a roughly 4.9% stake in a concurrent private placement.

Sep 21, 2026FOLLOW-UP

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics